News Releases

$

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Hero Chart

- The national campaign seeks to emphasize the unbearable burden ALGS has on patients and their families. - Mirum underscores its commitment to continued understanding of the rare liver disease through research and support of ALGS community. FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan.
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 14, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the first patient has been enrolled in Mirum’s Phase 2b VISTAS study evaluating volixibat in adult patients with primary sclerosing cholangitis (PSC), an idiopathic chronic
... Read More
Additional Formats
- Completion of maralixibat rolling NDA targeted for Q1 2021 - Expecting first-patient-in for volixibat studies in ICP and PSC, and maralixibat study in biliary atresia in Q1 2021 - Launching volixibat primary biliary cholangitis program in H2 2021 - European commercial leader hired in anticipation
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 8, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that on January 8, 2021 , the
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 4, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place virtually January 11-14, 2021 . Chris Peetz , Mirum’s president and chief executive officer, will
... Read More
Additional Formats